Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed)

Key Facts

Status: Open

Posted date: September 29, 2025

Opportunity ID: 360672

Opportunity number: RFA-TR-26-001

Opportunity category: Discretionary

Agency name: National Institutes of Health

Agency code: HHS-NIH11

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Cooperative Agreement
Category of Funding Activity
  • Health
Eligible Applicants
  • City or township governments
  • County governments
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
  • Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education
  • Others
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Small businesses
  • State governments
Tools
Categories (use these for quoted searches)
  • agency_code:hhs_nih11
  • category_of_funding_activity:health
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:city_or_township_governments
  • eligible_applicants:county_governments
  • eligible_applicants:independent_school_districts
  • eligible_applicants:native_american_tribal_governments_federally_recognized
  • eligible_applicants:native_american_tribal_organizations_other_than_federally_recognized_tribal_governments
  • eligible_applicants:nonprofits_having_a_501_c_3_status_with_the_irs_other_than_institutions_of_higher_education
  • eligible_applicants:nonprofits_that_do_not_have_a_501_c_3_status_with_the_irs_other_than_institutions_of_higher_education
  • eligible_applicants:others
  • eligible_applicants:private_institutions_of_higher_education
  • eligible_applicants:public_and_state_controlled_institutions_of_higher_education
  • eligible_applicants:small_businesses
  • eligible_applicants:state_governments
  • funding_instrument_type:cooperative_agreement
  • opportunity_category:discretionary
  • status:open
Description

This NOFO seeks to develop electronic nose technologies that mimic the olfactory system, leading to a robust diagnostic platform subject to validation and regulatory approval. A previous iteration demonstrated the feasibility of developing safe and effective biosensing technologies for volatile organic compound (VOC) signatures from human skin through systems engineering and artificial intelligence. VOCs are biomarkers that underlie the effects of a wide array of diseases. Under this iteration of the NOFO, improved sensing, detection, and analytical technologies will be developed for integration into tools for disease diagnosis and monitoring in everyday settings. These novel technologies will complement traditional blood analysis and other invasive, expensive, and highly technical procedures to monitor the onset, progression, and resolution of disease.NCATS’ vision is to bring more treatments for all people more quickly. The electronic nose platform is noninvasive and makes diagnosis in real time, in situ. This NOFO seeks to improve the translation of existing knowledge for the prevention and treatment of various diseases conditions.Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.

Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed)
This NOFO seeks to develop electronic nose technologies that mimic the olfactory system, leading to a robust diagnostic platform subject to validation and regulatory approval. A previous iteration demonstrated the feasibility of developing safe and effective biosensing technologies for volatile organic compound (VOC) signatures from human skin through systems engineering and artificial intelligence. VOCs are biomarkers that underlie the effects of a wide array of diseases. Under this iteration of the NOFO, improved sensing, detection, and analytical technologies will be developed for integration into tools for disease diagnosis and monitoring in everyday settings. These novel technologies will complement traditional blood analysis and other invasive, expensive, and highly technical procedures to monitor the onset, progression, and resolution of disease.NCATS’ vision is to bring more treatments for all people more quickly. The electronic nose platform is noninvasive and makes diagnosis in real time, in situ. This NOFO seeks to improve the translation of existing knowledge for the prevention and treatment of various diseases conditions.Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.
Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed)
Open
National Institutes of Health
Health
Cooperative Agreement
State governments
County governments
City or township governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Small businesses
Others
2025-09-29